Research location
Bronxville
New York, United States
Advertisement
Research activity in Bronxville
New York, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 19 trials and 19 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Bronxville
19 linked trials · page 1 of 1A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966 · 2024-02-21 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation
RECRUITING
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerNCT06632327 · 2024-12-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase 4 COPD and Suboptimal Inspiratory Flow RateNCT05165485 · 2022-01-07 · 1 site observation
COMPLETED
A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT03474081 · 2018-03-29 · 1 site observation
COMPLETED
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)NCT02465567 · 2015-06-30 · 1 site observation
COMPLETED
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT02164513 · 2014-06-30 · 1 site observation
COMPLETED
Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation HistoryNCT02138916 · 2014-06-13 · 1 site observation
COMPLETED
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseNCT01313676 · 2011-01-25 · 1 site observation
COMPLETED
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary DiseaseNCT01126437 · 2010-05-01 · 1 site observation
COMPLETED
Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)NCT01044459 · 2009-11-01 · 1 site observation
COMPLETED
Topcon 3D OCT-1000 Optical Coherence Tomography SystemNCT00792259 · 2008-10-01 · 1 site observation
COMPLETED
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPDNCT00419744 · 2007-01-01 · 1 site observation
COMPLETED
A Trial of BMS-512148 in Patients With Type 2 Diabetes MellitusNCT00263276 · 2005-12-01 · 1 site observation
COMPLETED
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)NCT00103922 · 2004-11-01 · 1 site observation
COMPLETED
Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.NCT00355342 · 2004-04-28 · 1 site observation
COMPLETED
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT00268216 · 2000-09-01 · 1 site observation
COMPLETED
Iressa Expanded Access Program (EAP)NCT00034879 · 2000-08-01 · 1 site observation
COMPLETED
TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.NCT00245739 · 1 site observation
APPROVED_FOR_MARKETING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.